MedPath

Investigation of efficacy and safety of switching from basal-bolus therapy to combination therapy with GLP-1 receptor agonist and basal insulin injection in type 2 diabetes

Not Applicable
Conditions
type 2 diabetes
Registration Number
JPRN-UMIN000013222
Lead Sponsor
Juntendo University Graduate School of Medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
30
Inclusion Criteria

Not provided

Exclusion Criteria

1)hypersensitivity to lixisenatide 2)patient with hypoglycemia 3)patient with serious liver and kidney disease 4)patient with proiferatibe retinopathy 5)during pregnancy and lactation.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
1.MAGE by CGM 2.Glucose fluctuation by SMBG
Secondary Outcome Measures
NameTimeMethod
1.change of C-peptide,glucagon and glucose during the meal test 2.frequency of hypoglycemia 3.frequency of adverse events
© Copyright 2025. All Rights Reserved by MedPath